HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China

Not yet recruiting

• Conditions: Endometrial Cancer; Ovarian Cancer; HER2 Expression; Cervical Cancer
• Interventions: Other: no intervention

• Registration Number: NCT06238284
• Lead Sponsor: Chongqing University Cancer Hospital

Brief Summary

This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-06
• Study First Submitted: 2024-01-25
• Study First Submitted QC: 2024-01-25
• Last Update Submitted: 2024-01-25
• Study Start: 2024-01-26
• Study First Posted: 2024-02-02
• Last Update Posted: 2024-02-02
• Primary Completion: 2024-03-31
• Study Completion: 2024-05-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

• Patients with primary gynecological malignant tumor confirmed by histopathology
• Women aged 18-75
• The expected survival time is greater than 12 weeks
• KPS > 60, ECOG score is 0-2
• All subjects voluntarily joined this study with informed consents, and had good compliance of follow-up

Exclusion Criteria

• Pregnant and lactating women
• Suffering from other malignant tumors in the past 5 years
• Patients who are not suitable for this study according to the investigator's judgment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Ovarian Cancer Group	no intervention	-
Cervical Cancer Group	no intervention	-
Endometrial Cancer Group	no intervention	-

Primary Outcome Measures

Name	Time	Method
HER2 status	from 2023.07 to 2024.05	HER2 exprssion level evaluated by pathologists